A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients
“Through comprehensive lab and mice tests we found that this SNP, although associated with reduced prostate cancer risk, is also associated with an aggressive type of this cancer,” Dr Srinivasan
Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly reduce the quality of life
Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of tumour is still responsible for one in eight male cancer
Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating
A team at the University of Cordoba and IMIBIC tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study
Early detection is critical when it comes to curing diseases like cancer, but not everyone has easy access to screening tools. For problems in the genitourinary (GU) tract (which includes
Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is
Prostate cancer is the second leading cause of cancer death among American men. A ground-breaking study, conducted by researchers from the University of Virginia, Mount Sinai, the University of Michigan,
Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal
